Article
CAR T cell therapy: newer approaches to counter resistance and cost
1 Apr 2020
Abstract excerpt
The genetically engineered Chimeric Antigen Receptor bearing T-cell (CAR T cell) therapy has been emerged as the new paradigm of cancer immunotherapy. However, recent studies have reported an increase in the number of relapsed haematological malignancies. This review provides newer insights into how the efficacy of CAR T cells might be increased by the application of new genome editing technologies, monitoring...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
